Document is current
Any future updates will be listed below
-
Authors
Siegel, Joshua S. http://orcid.org/0000-0002-5752-3641
Subramanian, Subha
Perry, Demetrius
Kay, Benjamin P. http://orcid.org/0000-0003-3628-8029
Gordon, Evan M. http://orcid.org/0000-0002-2276-5237
Laumann, Timothy O. http://orcid.org/0000-0002-0428-427X
Reneau, T. Rick http://orcid.org/0000-0002-0211-2482
Metcalf, Nicholas V.
Chacko, Ravi V.
Gratton, Caterina http://orcid.org/0000-0003-4607-7401
Horan, Christine
Krimmel, Samuel R.
Shimony, Joshua S.
Schweiger, Julie A.
Wong, Dean F. http://orcid.org/0000-0001-9343-8367
Bender, David A.
Scheidter, Kristen M.
Whiting, Forrest I.
Padawer-Curry, Jonah A.
Shinohara, Russell T.
Chen, Yong
Moser, Julia http://orcid.org/0000-0002-6219-415X
Yacoub, Essa
Nelson, Steven M.
Vizioli, Luca
Fair, Damien A. http://orcid.org/0000-0001-8602-393X
Lenze, Eric J.
Carhart-Harris, Robin http://orcid.org/0000-0002-6062-7150
Raison, Charles L.
Raichle, Marcus E.
Snyder, Abraham Z. http://orcid.org/0000-0002-3379-9627
Nicol, Ginger E.
Dosenbach, Nico U. F. http://orcid.org/0000-0002-6876-7078
- License Information
-
More Information
Article History
Received: 24 October 2023
Accepted: 29 May 2024
First Online: 17 July 2024
Competing interests
: Within the past year, J. S. Siegel has been an employee of Sumitomo Pharma America and received consulting fees from Longitude Capital. J. S. Siegel, N.U.F.D., T.O.L. and E.M.G. have submitted a provisional patent (patent no. 020949/US 15060-1787) for the use of precision functional mapping for measuring target engagement by experimental therapeutics. R.T.S. has received consulting compensation from Octave Bioscience and compensation for reviewership duties from the American Medical Association. C.L.R. serves as a consultant to Usona Institute and Novartis and receives research support from the Tiny Blue Dot Foundation. G.E.N. has received research support from Usona Institute (drug only). She has served as a paid consultant for Carelon, Alkermes, Inc., Sunovion Pharmaceuticals, Inc. and Novartis Pharmaceuticals Corp. T.O.L. holds a patent for taskless mapping of brain activity licenced to Sora Neurosciences and a patent for optimizing targets for neuromodulation, implant localization and ablation is pending. J. S. Siegel is a consultant and received stock options in Sora Neuroscience, and company that focuses on resting-state analysis. D.A.F. and N.U.F.D. are cofounders of Turing Medical Inc, have financial interest, may benefit financially if the company is successful in marketing FIRMM motion monitoring software products, may receive royalty income based on FIRMM technology developed at WUSOM and licenced to Turing Medical Inc. S.M.N., E.M.G. and T.O.L. have received consulting fees from Turing Medical Inc. D.F.W. is a consultant for Engrail Therapeutics and receives contract funds for WUSOM research studies from Eisai, Anavex and Roche. These potential conflicts of interest have been reviewed and are managed by WUSOM. The other authors declare no competing interests. All authors report no financial interest in psychedelics companies.
